Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Stage III-IV Melanoma

Melanoma

This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
Melanoma
II
Johnson, Douglas
NCT02965716
ECOGMELS1607

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Melanoma

Melanoma
N/A
Johnson, Douglas
NCT02173171
VICCMEL14103

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: